Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a recombinant bivalent norovirus vaccine in healthy children aged 6 months to 13 years
CTR20231609Phase 3Active
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd.
- Start
- May 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant bivalent norovirus vaccine in Noroviral gastroenteritis, sponsored by Lanzhou Institute of Biological Products Co., Ltd.. Started May 2023; status: active.
02
Drugs
recombinant bivalent norovirus vaccine
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on CTR20231609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231609.